HUP0300736A3 - Use of metal complexes containing perfluoroalkyl as contrast agents in mri-imaging for the representation of plaques, tumours and necroses - Google Patents

Use of metal complexes containing perfluoroalkyl as contrast agents in mri-imaging for the representation of plaques, tumours and necroses

Info

Publication number
HUP0300736A3
HUP0300736A3 HU0300736A HUP0300736A HUP0300736A3 HU P0300736 A3 HUP0300736 A3 HU P0300736A3 HU 0300736 A HU0300736 A HU 0300736A HU P0300736 A HUP0300736 A HU P0300736A HU P0300736 A3 HUP0300736 A3 HU P0300736A3
Authority
HU
Hungary
Prior art keywords
necroses
tumours
plaques
mri
imaging
Prior art date
Application number
HU0300736A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10040380A external-priority patent/DE10040380B4/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of HUP0300736A2 publication Critical patent/HUP0300736A2/hu
Publication of HUP0300736A3 publication Critical patent/HUP0300736A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HU0300736A 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mri-imaging for the representation of plaques, tumours and necroses HUP0300736A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10040380A DE10040380B4 (de) 2000-08-11 2000-08-11 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques
PCT/EP2001/008498 WO2002013874A2 (de) 2000-08-11 2001-07-23 Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen

Publications (2)

Publication Number Publication Date
HUP0300736A2 HUP0300736A2 (hu) 2003-09-29
HUP0300736A3 true HUP0300736A3 (en) 2010-01-28

Family

ID=7652860

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300736A HUP0300736A3 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mri-imaging for the representation of plaques, tumours and necroses

Country Status (26)

Country Link
EP (1) EP1307236A2 (es)
JP (1) JP2004506025A (es)
KR (1) KR20030022387A (es)
CN (1) CN1469757A (es)
AR (1) AR034139A1 (es)
AU (2) AU7754901A (es)
BG (1) BG107542A (es)
BR (1) BR0113188A (es)
CA (1) CA2419223A1 (es)
CZ (1) CZ2003392A3 (es)
DE (1) DE10066210B4 (es)
EE (1) EE200300061A (es)
HR (1) HRP20030173A2 (es)
HU (1) HUP0300736A3 (es)
IL (1) IL154385A0 (es)
MX (1) MXPA03001287A (es)
NO (1) NO20030604L (es)
NZ (1) NZ523932A (es)
PL (1) PL365596A1 (es)
RU (1) RU2290206C2 (es)
SK (1) SK1572003A3 (es)
TW (1) TWI296931B (es)
UA (1) UA82642C2 (es)
WO (1) WO2002013874A2 (es)
YU (1) YU10603A (es)
ZA (1) ZA200301949B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
DE102006021495A1 (de) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
US7887835B2 (en) * 2006-09-19 2011-02-15 Fujifilm Corporation Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
JP2011190183A (ja) * 2010-03-11 2011-09-29 Noguchi Institute フルオラス化糖結合型クラウンエーテル誘導体
US9976072B2 (en) 2014-03-26 2018-05-22 Chevron U.S.A. Inc. Multicarboxylate compositions and method of making the same
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
WO2018052037A1 (ja) 2016-09-14 2018-03-22 ダイキン工業株式会社 分枝含フッ素化合物
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
KR20210095168A (ko) 2018-11-23 2021-07-30 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
CN109867635A (zh) * 2019-02-14 2019-06-11 华东师范大学 一种t1型胶束磁共振成像造影剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
JPH10112939A (ja) * 1996-10-07 1998-04-28 Nec Corp 電源切替回路
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis

Also Published As

Publication number Publication date
CA2419223A1 (en) 2003-02-11
ZA200301949B (en) 2004-12-14
PL365596A1 (en) 2005-01-10
EE200300061A (et) 2004-12-15
AU2001277549B2 (en) 2007-02-08
MXPA03001287A (es) 2003-10-06
HUP0300736A2 (hu) 2003-09-29
KR20030022387A (ko) 2003-03-15
CN1469757A (zh) 2004-01-21
EP1307236A2 (de) 2003-05-07
BG107542A (bg) 2003-09-30
NZ523932A (en) 2007-07-27
HRP20030173A2 (en) 2005-04-30
DE10066210B4 (de) 2008-02-28
CZ2003392A3 (cs) 2003-09-17
RU2290206C2 (ru) 2006-12-27
SK1572003A3 (en) 2003-10-07
AU7754901A (en) 2002-02-25
WO2002013874A2 (de) 2002-02-21
BR0113188A (pt) 2003-06-24
AR034139A1 (es) 2004-02-04
NO20030604D0 (no) 2003-02-07
WO2002013874A8 (de) 2002-06-13
UA82642C2 (uk) 2008-05-12
YU10603A (sh) 2006-05-25
IL154385A0 (en) 2003-09-17
TWI296931B (en) 2008-05-21
JP2004506025A (ja) 2004-02-26
NO20030604L (no) 2003-04-11

Similar Documents

Publication Publication Date Title
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
AU2002367262A8 (en) Personal user agent
HUP0300736A3 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mri-imaging for the representation of plaques, tumours and necroses
IL158985A0 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
EP1465997A4 (en) USE OF BIOMOLECULAR OBJECTIVES IN THE TREATMENT AND VISUALIZATION OF TUMORS
EP1435988A4 (en) IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
EP1482985A4 (en) TECHNETIUM-DIPYRIDINE COMPLEXES AND METHODS OF USE THEREOF
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
AU2001261544A1 (en) Metal surface treatment agent
AU2002346644A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
EP1390689A4 (en) REDUCTION OF COHERENT ARTIFACTS IN AN INTERFEROMETER
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
IL174972A0 (en) Use of metal tricarbonyl complexes as radiotherapeutic chemotoxic agents
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
AU2003281146A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of intravascular thrombes
HUP0400262A3 (en) Glycopeptides, their preparation and use in the treatment of multiple sclerosis
AU2003233431A8 (en) Protamine-adenoviral vector complexes and methods of use
EP1416945A4 (en) IMPROVED HETEROPOLYMER COMPLEXES AND METHODS FOR THEIR USE
AU6022701A (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
IL160310A0 (en) The use of anthroquinones in the treatment of kidney disease
GB0022081D0 (en) Pyrazolone lanthanide complexes

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees